Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 2/2024

12-12-2023 | Colorectal Cancer | Original Article

CYP1B1-AS1 Delays the Malignant Progression of Colorectal Cancer by Binding with NOP58

Authors: Zhao Wu, Fei Cheng, Lebin Yuan, Xiaodong Li, Zhigang Li, Zeyu Huang, Shengping Mao, Xing Chen, Jiwei Wang, Bin Lai, Wei Shen

Published in: Digestive Diseases and Sciences | Issue 2/2024

Login to get access

Abstract

Background

Colorectal cancer (CRC) is a prevalent type of gastrointestinal cancer, and its poor prognosis is mainly attributed to the occurrence of invasion and metastasis. CYP1B1-AS1, as non-coding RNA, plays an important role in tumorigenesis and progression. However, the mechanism by which CYP1B1-AS1 acts in CRC is not yet understood.

Aims

The objective of this study was to investigate how CYP1B1-AS1 contributes to the development of CRC, and provide a base for CRC diagnosis and treatment.

Methods

RT-qPCR was used to detect the expression level of CYP1B1-AS1 in CRC and adjacent tissues. CCK-8, Edu, scratch healing, and transwell experiments were used to detect the changes of proliferation, migration, and invasion ability of CRC cells after overexpression or knockdown of CYP1B1-AS1 respectively. The RNA binding protein NOP58 combined with CYP1B1-AS1 was verified by RIP and RNA Pull-down experiments. Functional recovery experiments validated the interaction between CYP1B1-AS1 and NOP58 in CRC cells. The changes of EMT-related proteins were detected by Western blot, and the half-life of transcription factor SNAIL mRNA were detected by RT-qPCR after overexpression or knockdown of NOP58.

Results

CYP1B1-AS1 was found to be significantly downregulated in CRC compared to adjacent noncancerous tissues. Experiments conducted in vitro and in vivo confirmed that upregulation of CYP1B1-AS1 significantly inhibited the proliferation, migration, and invasion of CRC cells. In addition, CYP1B1-AS1 can directly bind to NOP58 and negatively regulate NOP58. The effect of overexpression CYP1B1-AS1 was reversed by NOP58 overexpression. NOP58 regulates the EMT process of CRC cells by affecting the stability of EMT-related transcription factor SNAIL mRNA, and then affects the progress of CRC.

Conclusion

This research proves that CYP1B1-AS1 can inhibit the occurrence of EMT in CRC by binding with NOP58, thus delaying the progress of CRC. This finding indicates that CYP1B1-AS1 may be a novel biomarker to improve the diagnosis and treatment of CRC.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 2021;71:209–249.PubMed
2.
Liang TJ, Wang HX, Zheng YY et al. APC hypermethylation for early diagnosis of colorectal cancer: a meta-analysis and literature review. Oncotarget 2017;8:46468–46479.CrossRefPubMedPubMedCentral
3.
Miller KD, Nogueira L, Mariotto AB et al. Cancer treatment and survivorship statistics, 2019. CA: Cancer J Clin 2019;69:363–85.PubMed
4.
Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009;136:629–641.CrossRefPubMed
5.
6.
Mahdi Khanifar M, Zafari Z, Sheykhhasan M. Crosstalk between long non-coding RNAs and p53 signaling pathway in colorectal cancer: a review study. Pathol Res Pract 2023;249:154756.CrossRefPubMed
7.
Zhang Y, Luo M, Cui X, O’Connell D, Yang Y. Long noncoding RNA NEAT1 promotes ferroptosis by modulating the miR-362-3p/MIOX axis as a ceRNA. Cell Death Differ 2022;29:1850–1863.CrossRefPubMedPubMedCentral
8.
Hua Q, Jin M, Mi B et al. LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis. J Hematol Oncol 2019;12:91.CrossRefPubMedPubMedCentral
9.
Yang Z, OuYang X, Zheng L, Dai L, Luo W. Long intergenic noncoding RNA00265 promotes proliferation of gastric cancer via the microRNA-144-3p/Chromobox 4 axis. Bioengineered 2021;12:1012–1025.CrossRefPubMedPubMedCentral
10.
Yao ZT, Yang YM, Sun MM et al. New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer. Cancer Commun 2022;42(2):117–140.CrossRef
11.
Li B, Kang H, Xiao Y et al. LncRNA GAL promotes colorectal cancer liver metastasis through stabilizing GLUT1. Oncogene 2022;41:1882–1894.CrossRefPubMed
12.
13.
14.
Ye T, Li LL, Peng XM, Li Q. CYP1B1-AS1 is a novel biomarker in glioblastoma by comprehensive analysis. Dis Mark 2021;2021:8565943.
15.
Ren J, Wang A, Liu J, Yuan Q. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma. Bioengineered 2021;12:4331–4348.CrossRefPubMedPubMedCentral
16.
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet 2019;394(10207):1467–1480.CrossRefPubMed
17.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: Cancer J Clin 2015;65:87–108.PubMed
18.
He D, Ma L, Feng R et al. Analyzing large-scale samples highlights significant association between rs10411210 polymorphism and colorectal cancer. Biomed Pharmacother Biomed Pharmacother 2015;74:164–8.CrossRefPubMed
19.
Lévy J, Cacheux W, Bara MA et al. Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth. Nat Cell Biol 2015;17:1062–1073.CrossRefPubMed
20.
Nishihara R, Wu K, Lochhead P et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095–1105.CrossRefPubMed
21.
Mittal V. Epithelial mesenchymal transition in tumor metastasis. Ann Rev Pathol 2018;13:395–412.CrossRef
22.
Lan Y, Xiao X, He Z et al. Long noncoding RNA OCC-1 suppresses cell growth through destabilizing HuR protein in colorectal cancer. Nucleic Acids Res 2018;46:5809–5821.CrossRefPubMedPubMedCentral
23.
Ma Y, Yang Y, Wang F et al. Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/β-catenin signalling pathway via suppression of activator protein 2α. Gut 2016;65:1494–1504.CrossRefPubMed
24.
Taniue K, Kurimoto A, Sugimasa H et al. Long noncoding RNA UPAT promotes colon tumorigenesis by inhibiting degradation of UHRF1. Proc Natl Acad Sci USA 2016;113:1273–1278.CrossRefPubMedPubMedCentral
25.
26.
Di W, Weinan X, Xin L et al. Long noncoding RNA SNHG14 facilitates colorectal cancer metastasis through targeting EZH2-regulated EPHA7. Cell Death Dis 2019;10:514.CrossRefPubMedPubMedCentral
27.
Zheng S, Lin F, Zhang M, Fu J, Ge X, Mu N. AK001058 promotes the proliferation and migration of colorectal cancer cells by regulating methylation of ADAMTS12. Am J Transl Res 2019;11:5869–5878.PubMedPubMedCentral
28.
Köster T, Marondedze C, Meyer K, Staiger D. RNA-binding proteins revisited—the emerging Arabidopsis mRNA INTERACTOME. Trends Plant Sci 2017;22:512–526.CrossRefPubMed
29.
Hentze MW, Castello A, Schwarzl T, Preiss T. A brave new world of RNA-binding proteins. Nat Rev Mol Cell Biol 2018;19:327–341.CrossRefPubMed
30.
Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteom Bioinform 2016;14:42–54.CrossRef
31.
Cervantes M, Forné I, Ranjit S, Gratton E, Imhof A, Sassone-Corsi P. BMAL1 associates with NOP58 in the nucleolus and contributes to pre-rRNA processing. iScience 2020;23:101151.CrossRefPubMedPubMedCentral
32.
33.
Qi L, Sun B, Yang B, Lu S. PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer. Breast Cancer Res Treat 2022;193:305–318.CrossRefPubMed
Metadata
Title
CYP1B1-AS1 Delays the Malignant Progression of Colorectal Cancer by Binding with NOP58
Authors
Zhao Wu
Fei Cheng
Lebin Yuan
Xiaodong Li
Zhigang Li
Zeyu Huang
Shengping Mao
Xing Chen
Jiwei Wang
Bin Lai
Wei Shen
Publication date
12-12-2023
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2024
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-023-08206-7

Other articles of this Issue 2/2024

Digestive Diseases and Sciences 2/2024 Go to the issue

Original Article

Historical Obesity and Early-Onset Cancers: A Propensity-Weighted Analysis of the National Health and Nutrition Examination Survey

Original Article

Acute Nonvariceal Upper Gastrointestinal Bleeding in Patients Using Anticoagulants: Does the Timing of Endoscopy Affect Outcomes?

Original Article

Characteristics of Esophageal Motility and Associated Symptom Profiles in Patients with Esophageal Diverticulum: A Study Based on High-Resolution Impedance Manometry

Original Article

Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis

Concise Commentary

Concise Commentary: Red Mucosa Is Not Enough—Another Approach to Treating Dyspeptic Symptoms

Original Article

Limitations of Noninvasive Tests-Based Population-Level Risk Stratification Strategy for Nonalcoholic Fatty Liver Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits